Donald McCaffrey
Amministratore Delegato presso RESVERLOGIX CORP.
Patrimonio netto: 513 843 $ in data 30/06/2024
Profilo
Donald J.
McCaffrey is the founder.
He founded Resverlogix Corp.
in 2000, where he currently holds the titles of Chairman, President, CEO & Secretary.
He also founded Zenith Capital Corp.
(Alberta) in 2013, where he currently holds the titles of Chairman, President & Chief Executive Officer.
In addition to his founding positions, Mr. McCaffrey has held former positions as Director at Trillium Therapeutics ULC from 2004 to 2006, and as Director at ProMIS Neurosciences, Inc.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ZENITH CAPITAL CORP.
1.72% | 02/01/2024 | 2 615 324 ( 1.72% ) | 313 839 $ | 30/06/2024 |
RESVERLOGIX CORP.
1.92% | 02/01/2024 | 5 263 266 ( 1.92% ) | 200 004 $ | 30/06/2024 |
Posizioni attive di Donald McCaffrey
| Società | Posizione | Inizio |
|---|---|---|
| RESVERLOGIX CORP. | Amministratore Delegato | 25/04/2003 |
| ZENITH CAPITAL CORP. | Amministratore Delegato | 10/04/2013 |
Precedenti posizioni note di Donald McCaffrey
| Società | Posizione | Fine |
|---|---|---|
| TRILLIUM THERAPEUTICS | Direttore/Membro del Consiglio | 27/03/2006 |
| PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| RESVERLOGIX CORP. | Health Technology |
| ZENITH CAPITAL CORP. | Health Technology |
| Aziende private | 1 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- Donald McCaffrey
